[
  {
    "ts": null,
    "headline": "2 Stocks to Buy With Less Than $50",
    "summary": "Pfizer is slowly building a foundation that will help its business recover from recent headwinds.  Encouraging developments on the clinical front should boost shares of cancer specialist Exelixis.  Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices.",
    "url": "https://finnhub.io/api/news?id=e75db1c612e2941d81b7b484c215fb672885a190680e3f3463824e0d8d29adf6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751629500,
      "headline": "2 Stocks to Buy With Less Than $50",
      "id": 135755310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is slowly building a foundation that will help its business recover from recent headwinds.  Encouraging developments on the clinical front should boost shares of cancer specialist Exelixis.  Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices.",
      "url": "https://finnhub.io/api/news?id=e75db1c612e2941d81b7b484c215fb672885a190680e3f3463824e0d8d29adf6"
    }
  },
  {
    "ts": null,
    "headline": "HER2+ Breast Cancer Market Analysis and Forecasts Report 2025-2035 | Emerging Markets and Players Shape Future of HER2-Positive Cancer Solutions",
    "summary": "The global HER2-positive breast cancer market is rapidly evolving due to rising prevalence and demand for targeted therapies. HER2-positive breast cancer, characterized by overexpression of HER2 protein leading to uncontrolled cell growth, is driving market demand for advanced treatment options. Key innovations, including monoclonal antibodies, ADCs, and immunotherapies, offer personalized treatments, enhancing patient outcomes and market expansion. However, high treatment costs and regulatory c",
    "url": "https://finnhub.io/api/news?id=9ac7d4e39fd65f0c98acab0228d4c1f225652d71137f87f90160f68270302b31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751624880,
      "headline": "HER2+ Breast Cancer Market Analysis and Forecasts Report 2025-2035 | Emerging Markets and Players Shape Future of HER2-Positive Cancer Solutions",
      "id": 135756441,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global HER2-positive breast cancer market is rapidly evolving due to rising prevalence and demand for targeted therapies. HER2-positive breast cancer, characterized by overexpression of HER2 protein leading to uncontrolled cell growth, is driving market demand for advanced treatment options. Key innovations, including monoclonal antibodies, ADCs, and immunotherapies, offer personalized treatments, enhancing patient outcomes and market expansion. However, high treatment costs and regulatory c",
      "url": "https://finnhub.io/api/news?id=9ac7d4e39fd65f0c98acab0228d4c1f225652d71137f87f90160f68270302b31"
    }
  },
  {
    "ts": null,
    "headline": "Medicus Pharma: High-Risk, But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment",
    "summary": "Medicus Pharma: High-Risk, But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment",
    "url": "https://finnhub.io/api/news?id=62f91dfe503b61d8fd4481ff0401393f8f7bd85151f85844e4f0ffb8c9caf35a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751622563,
      "headline": "Medicus Pharma: High-Risk, But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment",
      "id": 135752696,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=62f91dfe503b61d8fd4481ff0401393f8f7bd85151f85844e4f0ffb8c9caf35a"
    }
  },
  {
    "ts": null,
    "headline": "Trending tickers: TripAdvisor, Bitmine, WolfSpeed, BYD and AstraZeneca",
    "summary": "The latest investor updates on stocks that are trending on Friday",
    "url": "https://finnhub.io/api/news?id=c60188bc6927885b2abfbe77b09168d74f0c02fe3f378cf9e9d1f6c5c2a1b8e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751618606,
      "headline": "Trending tickers: TripAdvisor, Bitmine, WolfSpeed, BYD and AstraZeneca",
      "id": 135749747,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The latest investor updates on stocks that are trending on Friday",
      "url": "https://finnhub.io/api/news?id=c60188bc6927885b2abfbe77b09168d74f0c02fe3f378cf9e9d1f6c5c2a1b8e0"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Advances HYMPAVZI After Successful Hemophilia Trial Results",
    "summary": "Pfizer Inc. (NYSE:PFE) ranks among the best set-it-and-forget-it stocks to buy. On June 26, Pfizer Inc. (NYSE:PFE) declared that the Phase 3 BASIS research results showed that its medication HYMPAVZI (marstacimab) was superior to other inhibitors in treating hemophilia A or B patients. Comparing HYMPAVZI to on-demand treatment, the trial revealed that the former decreased […]",
    "url": "https://finnhub.io/api/news?id=3d181fc49ed5b0de4b58d63973a24a94f7525ff4cc2fccb9e1f13cd7a40c5c65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751613758,
      "headline": "Pfizer Advances HYMPAVZI After Successful Hemophilia Trial Results",
      "id": 135756443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) ranks among the best set-it-and-forget-it stocks to buy. On June 26, Pfizer Inc. (NYSE:PFE) declared that the Phase 3 BASIS research results showed that its medication HYMPAVZI (marstacimab) was superior to other inhibitors in treating hemophilia A or B patients. Comparing HYMPAVZI to on-demand treatment, the trial revealed that the former decreased […]",
      "url": "https://finnhub.io/api/news?id=3d181fc49ed5b0de4b58d63973a24a94f7525ff4cc2fccb9e1f13cd7a40c5c65"
    }
  },
  {
    "ts": null,
    "headline": "Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons",
    "summary": "The House Judiciary Committee has subpoenaed Dr. Philip Dormitzer, a former Pfizer Inc. (NYSE:PFE) executive, in connection with an investigation into claims that the company intentionally delayed the release of clinical testing results for its COVID-19 vaccine until after the 2020 presidential election. The move signals an escalation in the panel's probe into whether political considerations influenced Pfizer's vaccine announcement timeline. Dormitzer, who later joined British drugmaker GSK Plc",
    "url": "https://finnhub.io/api/news?id=48993a5981a34668efcce3c69cb0d4a5a3ee369061748666ad865055131688f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751589022,
      "headline": "Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons",
      "id": 135745573,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The House Judiciary Committee has subpoenaed Dr. Philip Dormitzer, a former Pfizer Inc. (NYSE:PFE) executive, in connection with an investigation into claims that the company intentionally delayed the release of clinical testing results for its COVID-19 vaccine until after the 2020 presidential election. The move signals an escalation in the panel's probe into whether political considerations influenced Pfizer's vaccine announcement timeline. Dormitzer, who later joined British drugmaker GSK Plc",
      "url": "https://finnhub.io/api/news?id=48993a5981a34668efcce3c69cb0d4a5a3ee369061748666ad865055131688f9"
    }
  }
]